TCL Archive GPC Biotech’s Satraplatin Fails To Extend Survival In Hormone-Refractory Prostate Cancer. November 2, 2007
Primary Source NCCS Networker Volume 10 Issue 2, Summer/Fall 1996 Special Commemorative Issue August 13, 1996
TCL Archive Celebrex Studies Show Polyp Reduction, Point To Challenges In Biomarker Validation April 28, 2006
TCL Archive Phase II Study Meets Primary Endpoint, Demonstrating Overall Survival of 5.2 Months September 27, 2013
